These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 17418008)

  • 1. [Efficacy in advanced breast cancer should be evaluated by time to progression].
    Song ST
    Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(2):73-5. PubMed ID: 17418008
    [No Abstract]   [Full Text] [Related]  

  • 2. Adherence to quality indicators and survival in patients with breast cancer.
    Cheng SH; Wang CJ; Lin JL; Horng CF; Lu MC; Asch SM; Hilborne LH; Liu MC; Chen CM; Huang AT
    Med Care; 2009 Feb; 47(2):217-25. PubMed ID: 19169123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
    Haffty BG; Yang Q; Moran MS; Tan AR; Reiss M
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1006-13. PubMed ID: 18262731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update in the treatment of locally advanced breast cancer: a multidisciplinary approach.
    Franceschini G; Terribile D; Magno S; Fabbri C; D'Alba PF; Chiesa F; Di Leone A; Masetti R
    Eur Rev Med Pharmacol Sci; 2007; 11(5):283-9. PubMed ID: 18074936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are many community hospitals undertreating breast cancer?: lessons from 24,834 patients.
    Gutierrez JC; Hurley JD; Housri N; Perez EA; Byrne MM; Koniaris LG
    Ann Surg; 2008 Aug; 248(2):154-62. PubMed ID: 18650623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical criteria as predictive factors of response to primary hormone therapy in locally advanced breast cancer.
    Tiezzi DG; de Andrade JM; Marana HR; Garieri AP; de Paula Philbert PM
    Breast J; 2009; 15(4):333-8. PubMed ID: 19496783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time trends in the outcome of elderly patients with breast cancer.
    Hughes S; Barbachano Y; Ashley S; Yap YS; Popat S; Allen M; Della-Rovere UQ; Johnston S; Smith I; O'Brien M
    Breast J; 2008; 14(2):158-63. PubMed ID: 18312470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of dedicated breast surgeons on the short-term outcomes in breast cancer.
    Zork NM; Komenaka IK; Pennington RE; Bowling MW; Norton LE; Clare SE; Goulet RJ
    Ann Surg; 2008 Aug; 248(2):280-5. PubMed ID: 18650639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
    Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
    Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardized evaluation of regional and institutional breast cancer outcomes.
    Beatty JD; Rees J; Atwood M; Pugliese M; Bolejack V
    Am J Surg; 2008 May; 195(5):636-40; discussion 640. PubMed ID: 18374891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.
    Cristofanilli M; Valero V; Buzdar AU; Kau SW; Broglio KR; Gonzalez-Angulo AM; Sneige N; Islam R; Ueno NT; Buchholz TA; Singletary SE; Hortobagyi GN
    Cancer; 2007 Oct; 110(7):1436-44. PubMed ID: 17694554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A proportional hazards cure model for the analysis of time to event with frequently unidentifiable causes.
    Dahlberg SE; Wang M
    Biometrics; 2007 Dec; 63(4):1237-44. PubMed ID: 18078485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival impact of integrative cancer care in advanced metastatic breast cancer.
    Block KI; Gyllenhaal C; Tripathy D; Freels S; Mead MN; Block PB; Steinmann WC; Newman RA; Shoham J
    Breast J; 2009; 15(4):357-66. PubMed ID: 19470134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inflammatory breast cancer: clinical course, diagnosis and treatment].
    Borisov VI; Chkhikvadze TV
    Vopr Onkol; 2008; 54(1):86-9. PubMed ID: 18416065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome with interstitial brachytherapy boost in the treatment of women with early-stage breast cancer.
    Neumanova R; Petera J; Frgala T; Dusek L; Jarkovsky J; Kuricka R
    Neoplasma; 2007; 54(5):413-23. PubMed ID: 17688371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.
    Pierce JP; Natarajan L; Marshall J; Messer K
    J Natl Cancer Inst; 2007 Jun; 99(11):900; author reply 900-1. PubMed ID: 17551155
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.
    Kurt M; Altundag K
    J Natl Cancer Inst; 2007 Jun; 99(11):899-900; author reply 900-1. PubMed ID: 17551152
    [No Abstract]   [Full Text] [Related]  

  • 18. Neoadjuvant systemic therapy and the surgical management of breast cancer.
    Waljee JF; Newman LA
    Surg Clin North Am; 2007 Apr; 87(2):399-415, ix. PubMed ID: 17498534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haplotypes of XRCC1 and survival outcome in patients with metastatic breast cancer.
    Bewick MA; Conlon MS; Lafrenie RM
    Breast Cancer Res Treat; 2009 Oct; 117(3):667-9. PubMed ID: 19127428
    [No Abstract]   [Full Text] [Related]  

  • 20. Do very young Korean breast cancer patients have worse outcomes?
    Kim JK; Kwak BS; Lee JS; Hong SJ; Kim HJ; Son BH; Ahn SH
    Ann Surg Oncol; 2007 Dec; 14(12):3385-91. PubMed ID: 17899295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.